Sight Sciences Stock Rises Following New Buy Rating and $14 Price Target
Shares of Sight Sciences, Inc. (SGHT) advanced after financial analysts initiated coverage on the medical device maker with a Buy rating and a $14 price forecast. The upbeat coverage points to potential expansion in the company's core eye care divisions and higher operational efficiency.
The momentum stems from accelerating adoption of the firm's OMNI glaucoma platform and TearCare dry eye system. Recent commercial reimbursement expansion by insurer Aetna added about 25 million eligible members for glaucoma treatments. Meanwhile, dry eye revenue jumped 703% year over year in the second quarter to $2.7 million as Medicare coverage expanded. Driven by these trends and lower operating costs, leadership raised its full-year 2026 revenue forecast to $88 million to $92 million.
Moving forward, key factors to watch include the company's progress toward reducing cash consumption and navigating competitive pressures. Investors will also monitor the outcome of a $55.4 million patent judgment against Alcon, which is currently under appeal, alongside further potential reimbursement expansions for its medical devices.
Key points
- Analysts initiated coverage on Sight Sciences, Inc. (SGHT) with a Buy rating and a $14 price target.
- Second-quarter dry eye revenue rose 703% year over year to $2.7 million amid expanding Medicare coverage.
- Commercial insurer Aetna expanded coverage for eligible glaucoma procedures to approximately 25 million members.
- Management raised its 2026 revenue outlook to a range of $88 million to $92 million.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Sight Sciences stock rise?
Shares rose after analysts initiated coverage on the company with a Buy rating and a $14 price target, citing growth in its glaucoma and dry eye treatment businesses.
What is the 2026 revenue forecast for Sight Sciences?
Management expects 2026 revenue to land between $88 million and $92 million, representing full-year growth of approximately 14% to 19%.
What products drive growth for Sight Sciences?
Growth is primarily driven by its OMNI glaucoma treatment platform and TearCare dry eye system, supported by expanded commercial and Medicare reimbursement coverage.